3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
2
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
4
Squamous Cell Carcinoma of Head and Neck
3
Esophageal Squamous Cell Carcinoma
3
Esophageal Neoplasms
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Recurrence
2
Neoplasm Metastasis
2
Nasopharyngeal Carcinoma
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Advanced Gastric Cancer
2
Thoracic Neoplasms
1
Solid Tumor
1
Small Cell Lung Carcinoma
1
Respiratory Tract Neoplasms
1
Respiratory Tract Diseases
1
Osteosarcoma
1
Neoplasms by Site
1
Mouth Neoplasms
1
Lung Neoplasms
1
Lung Diseases
1
Liver Diseases
1
Hodgkin Disease
1
Hematologic Neoplasms
1
Gestational Trophoblastic Disease
1
Gastrointestinal Neoplasms
1
Interventions
Ifosfamide
17
Methotrexate
16
Doxorubicin
14
Filgrastim
13
Etoposide
12
Cisplatin
12
Cyclophosphamide
10
Gemcitabine
9
Leucovorin
8
Sirolimus
6
Carboplatin
6
Topotecan
5
Irinotecan
5
Granulocyte Colony-Stimulating Factor
5
Temozolomide
4
Sorafenib
4
Radiotherapy
4
Peripheral Blood Stem Cell Transplantation
4
Docetaxel
4
trimetrexate glucuronate
3
temsirolimus
3
dinutuximab
3
cixutumumab
3
apatinib
3
Vincristine
3
Specimen Handling
3
Oxaliplatin
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Imatinib Mesylate
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Osteosarcoma
×
camrelizumab
×
Clear all
NCT03359018
2020-05-19
APFAO
Peking University People's Hospital
Phase 2
Completed
43 enrolled